33
Participants
Start Date
June 12, 2023
Primary Completion Date
August 26, 2024
Study Completion Date
August 26, 2024
EYE103
EYE103 is a humanized antibody formulated for IVT administration
Caba, Argentina, Caba
Hagerstown, MD, Hagerstown
West Columbia, SC, West Columbia
Pompano Beach, Pompano Beach
Nashville, TN, Nashville
Knoxville, TN, Knoxville
Germantown, TN, Germantown
Lemont, NV, Lemont
Plano, TX, Plano
Dallas, TX, Dallas
The Woodlands, TX, The Woodlands
Bellaire, TX, Bellaire
Katy, TX, Katy
San Antonio, TX, San Antonio
McAllen, TX, McAllen
Round Rock, TX, Round Rock
Austin, TX, Austin
Amarillo, TX, Amarillo
Abilene, TX, Abilene
Lakewood, CO, Lakewood
Colorado Springs, Colorado, Colorado Springs
Phoenix, AZ, Phoenix
Reno, NV, Reno
Bakersfield, CA, Bakersfield
Mountain View, CA, Mountain View
Modesto, CA, Modesto
Sacramento, CA, Sacramento
Sacramento, CA, Sacramento
Ciudad Autonoma Buenos Aires, Ciudad Autonoma de Buenos Aires
Arecibo, PR, Arecibo
London, England, London
London, UK, London
Lead Sponsor
EyeBiotech Ltd.
INDUSTRY